Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission
Bibliographic record
Abstract
BACKGROUND AND AIMS: despite the established use of intravenous (IV) vedolizumab to treat inflammatory bowel disease, there is growing interest in exploring the advantages of the novel subcutaneous (SC) route. However, comprehensive real-world evidence regarding the extended safety and effectiveness remain scarce. METHODS: inflammatory bowel diseases (IBD) patients on IV vedolizumab treatment in clinical remission from 24 Spanish hospitals were given the option to transition to SC injections (where this formulation was available) or to remain on IV, whereas patients from centers without access to SC vedolizumab remained on IV therapy. Data encompassing clinical disease activity, biochemical markers, adverse events, treatment persistence, and disease-related outcomes were retrospectively gathered from prospectively maintained clinical records at baseline, and at weeks 12, 24, and 48. RESULTS: a total of 207 patients were identified and 23 were excluded as they were not in clinical remission, resulting in a final total of 184 patients included in the study. Of these, 53 (28.8 %) remained on IV vedolizumab, while 131 (71.2 %) transitioned to SC. There were 108 (58.7 %) patients with ulcerative colitis and 76 (41.3 %) with Crohn's disease. Both groups had comparable demographic characteristics, except for Crohn's disease behavior, with non-inflammatory non-stricturing pattern (B1 Montreal classification) being predominant among patients who transitioned to SC (p = 0.023). No differences were observed in drug persistence (log rank test p = 0.82). Clinical, biochemical and fecal calprotectin remission at the different time-points were comparable at each time point with the exception of clinical remission at week 12, favoring SC over IV. Drug intensification occurred in 24.5 % of patients on IV versus none on SC, p < 0.0001. Safety was consistent with that previously reported, and there were no differences between the groups (13 [8 %] SC vs 1 [2.1 %] IV, p = 0.059), most being mild in nature. CONCLUSIONS: transitioning from IV to SC vedolizumab in patients with IBD in remission showed a comparable effectiveness to maintain disease remission and persistence. Patients on IV are more likely to require drug intensification during follow-up.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".